Clinical Trial Update: A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating the combination of BIBF 1120 (nintedanib) with paclitaxel and carboplatin in advanced non-small-cell lung cancer has be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED